29 July 2021 | News
EBITDA was posted at Rs 400 crores
Image Credit: Shutterstock
Laurus Labs has announced its Q1 FY22 results. The total net revenue was at Rs 1,279 crores, up 31 per cent (Y-o-Y), EBITDA at Rs 400 crores, up 41 per cent (Y-o-Y); EBITDA margins at 31 per cent; PAT at Rs 241 crore, up 40 per cent (Y-o-Y) and PAT margins at 19 per cent (Y-o-Y).
Commenting on the results announcement, Dr Satyanarayana Chava - CEO, Laurus Labs said, “Our synthesis business retained its growth momentum powered by the increased business from the existing clients and new clients; the segment registered strong growth with +95 per cent YoY, with ongoing commercial supplies for four products. In the API segment, oncology and ARV APIs registered healthy growth. In contrast, revenue from our other API witnessed a slowdown, and the growth is expected to restore from Q2 FY22, we remain confident of maintaining a growth trajectory in the Generic API business for FY22. In addition, Laurus Bio started contributing to the revenue and would add more from Q2 FY22, with the new fermentation capacities added in recombinant food protein.”
VV Ravi Kumar, ED and CFO, Laurus Labs said, "Our performance focus is on growth driven by superior execution and completing our Future Ready strategy with manufacturing capacity expansions - a combination of brown and greenfield in API, FDF, and Synthesis divisions. With sustained business opportunities, we remain confident of achieving sustainable return ratios in the FY2022-23 and beyond.”